ALDX - Company ID 0001341235
The table below shows Aldeyra Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$5.11M | -$12.47M | -$9.97M | -$9.44M | -$12.87M | -$13.47M |
| Capital expenditure | - | - | - | $0.00 | $16.32K | $7.81K |
| Investing cash flow | $0.00 | $7.29M | -$30.38M | $30.00M | -$58.03M | -$7.81K |
| Dividends paid | - | - | - | - |
Aldeyra Therapeutics, Inc. reported operating cash flow of -$33.35M for fiscal year 2025. That is up 22.8% from -$43.21M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$19.22M (FY 2017) to -$33.35M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $71.14K | $1.00M | $18.19K | $52.56K | $23.32K | $74.06M |